AstraZeneca, Ionis Heart Drug Wainua Fails Pivotal Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- AstraZeneca said Wainua failed to outperform placebo in a pivotal trial for ATTR-CM (transthyretin-mediated amyloid cardiomyopathy), failing to reduce cardiovascular death and clinical events
- Wainua targets transthyretin-mediated amyloid cardiomyopathy, a condition the source describes as an increasingly competitive area for biopharma companies
- AstraZeneca partnered with Ionis Pharmaceuticals on Wainua, making the smaller biotech directly exposed to the readout
- AstraZeneca's U.S. shares fell roughly 8% in premarket trading, with London-listed shares down 9% early Thursday
- Ionis shares dropped 12% in premarket hours, reflecting its direct stake as AstraZeneca's development partner on the drug
Why it matters: Both partners took clear market hits — AstraZeneca down ~8-9% and Ionis down 12% premarket — because the trial failure eliminates Wainua in a cardiovascular indication the source says is drawing increasing competition from other biopharma companies, narrowing AstraZeneca's cardiovascular pipeline at a moment of rising rivalry.
